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Objectives: Antibiotics are commonly classified into bactericidal and bacteriostatic agents based on their
antimicrobial action. We aimed to assess whether this distinction is clinically relevant.
Methods: OVID MEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials (CENTRAL) and relevant
references and conference proceedings using the Web of Science and Scopus databases were searched for
randomized controlled trials comparing bactericidal with bacteriostatic antibiotics for treatment of severe infec-
tions. Main outcome measures were clinical cure rates and overall mortality. Abstracts of studies selected in the
database search were screened by one reviewer; full-text screening and data extraction were performed by three
independent reviewers.
Results: Thirty-three studies were included. Approximately half of patients were treated with bacteriostatic
monotherapy. Infections covered were pneumonia (n¼13), skin and soft tissue infections (n¼8), intra-
abdominal infections (n¼4) and others (n¼8). Neither clinical cure rates [risk ratio (RR), 0.99; 95% CI, 0.97–
1.01; P¼0.11] nor mortality rates (RR, 0.91; 95% CI, 0.76–1.08; P¼0.28) were different between patients treated
with bactericidal drugs and those treated with bacteriostatic drugs. Subgroup analyses showed a benefit for clin-
ical cure rates associated with linezolid and increased mortality associated with tigecycline. In meta-regression,
clinical cure rates remained higher in patients treated with linezolid (P¼0.01); tigecycline displayed a close to
significant association with increased mortality (P¼0.05) if compared with other bacteriostatic agents.
Conclusions: The categorization of antibiotics into bacteriostatic and bactericidal is unlikely to be relevant in
clinical practice if used for abdominal infections, skin and soft tissue infections and pneumonia. Because
we were not able to include studies on meningitis, endocarditis or neutropenia, no conclusion regarding these
diseases can be drawn.
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Introduction
The distinction between bactericidal and bacteriostatic antibiotics
is a successful concept to discriminate antibiotics that kill
bacteria—‘bactericidal’—from antibiotics that inhibit bacterial
growth, i.e. ‘bacteriostatic’. This classification is applied in major
textbooks of medicine and infectious diseases, clinical guidelines
and advertisements of novel antibiotics.1 – 5 The intuitively under-
standable concept between the two groups of antibiotics sug-
gests that bactericidal drugs have more powerful antibacterial
action and are able to kill bacteria. In contrast, bacteriostatic anti-
biotics are assumed to require phagocytic cells to definitely clear
bacteria and are therefore thought to be less effective without
an efficient immune response. This theoretical model has led to
the recommendation that severely ill and immunosuppressed
patients with bacterial infections should be treated with bacteri-
cidal antibiotics.2 – 4 Furthermore, some specific conditions are
also thought to require bactericidal antibiotics, such as endocar-
ditis.1 The cardiac valves are considered as focal, immunosup-
pressed regions poorly accessible for phagocytic cells. Therefore,
a phagocyte-independent killing by bactericidal drugs is generally
recommended under such circumstances.
Unfortunately, there are no clinical data supporting the con-
cept of bacteriostatic versus bactericidal antibiotics. This is quite
remarkable given the major influence on recommendations for
treatment of severely ill patients. The reason may lie in the diffi-
culties of assessing a drug class effect in a clinically meaning-
ful way.
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The main challenge is that during bacterial infection and
its treatment, relevant clinical outcomes such as cure rates and
mortality are influenced by three main factors: the host, the
pathogen and the drug. A drug class effect can only be secondary
to these three main factors and is therefore difficult to assess. Our
methodological assumption was that the drug class effect ‘bac-
tericidal versus bacteriostatic’ may be measurable if the three
main factors—host, drugs and pathogens—are as heterogeneous
as possible. If the common denominator is limited to the differ-
ence between bacteriostatic and bactericidal drugs amongst dif-
ferent clinical trials, the results may be reduced to the difference
between bactericidal and bacteriostatic antibiotics. This approach
introduces a meta-level that is beyond the range of a single ran-
domized trial. We therefore conducted a meta-analysis including
a wide variety of prospective clinical trials using bacteriostatic ver-
sus bactericidal antibiotic drugs for the treatment of patients with
severe bacterial infections. The main outcome measures were
clinical outcome and overall mortality.
Methods
Definitions
Severity
Requirement of hospitalization was used as a determinant to screen for
severity, unless the authors explicitly provided a definition for severity
in the study. Studies including patients with different levels of severity,
such as e.g. pneumonia and bronchitis, were excluded. Furthermore,
studies performed with relatively benign infections were excluded
(i.e. infections in the oral cavity, uncomplicated otolaryngeal infections,
uncomplicated gastrointestinal infections, sexually transmitted diseases,
Lyme disease, exacerbation of chronic bronchitis, pneumonia in the out-
patient setting etc.). Chronic infections such as diabetic foot infections
were excluded under the assumption that successful antibiotic therapy
in this setting does not rely on rapid killing but rather elimination of the bio-
film, vascular supply and joint and bone involvement.
Antibiotics
In the bacteriostatic antibiotic patient group, bacteriostatic single therapy
only without the concomitant use of any bactericidal drug was allowed,
with few exceptions: if all three authors agreed that the bactericidal com-
ponent of the combination therapy had no effect on bacteria, these
studies were included as well. Seven studies met these criteria.6 – 12
Six out of seven allowed the use of aztreonam in case of infection with
Gram-positive bacteria; one study allowed aminoglycosides in case of pro-
ven aminoglycoside resistance of Staphylococcus aureus infection.6 The
rate of resistance was similar between bacteriostatic and bactericidal anti-
biotics. For the seven studies with combination therapy, only the microbio-
logically confirmed cases were extracted for analysis in the clinical cure
groups. In all other studies, the ITT population was assessed. If no ITT
population was available, results from PP analyses were extracted.
In the bactericidal antibiotic treatment group, combination therapy
was allowed. Antibiotics were defined as bactericidal and bacteriostatic
according to a classification obtained from a major textbook of infectious
diseases, with one important exception (Table 1).3 Aminoglycosides act at
the ribosome and are therefore classified as bacteriostatic by some
authors. At higher concentrations, however, aminoglycosides display a
very rapid bactericidal effect. Due to considerations regarding side effects,
aminoglycosides are recommended to be given once daily at high con-
centrations for most indications.13 Therefore, aminoglycosides are most
likely to be bactericidal in routine clinical practice and were classified
accordingly.
Studies using inappropriate antibiotics in terms of microbiological
spectrum were excluded. Hence, possible differences are not attributable
to resistance of bacteria.
Outcomes
For the primary endpoint, clinical outcome as defined by the respective
study authors was used. Secondary endpoints were mortality and relapse
rates. Relapse rates were defined as recurrence of signs and symptoms
associated with the primary infection during follow-up after initial clinical
resolution or ‘relapse’ as defined by the authors. Subgroup analyses for dif-
ferent diseases were performed.
Data sources and searches
With the help of an experienced librarian with expertise in literature search
for systematic reviews and meta-analyses, we performed an electronic
search of OVID MEDLINE, EMBASE and The Cochrane Central Register of
Controlled Trials (CENTRAL). We also searched relevant references of
included studies and conference proceedings using the Web of Science
and Scopus databases. No time limits were applied. The search strategy
is displayed in detail in Figure S1 (available as Supplementary data at
JAC Online).
Study selection
We included all randomized controlled trials comparing bacteriostatic ver-
sus bactericidal antibiotics in patients with serious bacterial infections
requiring hospitalization. There was no restriction by study site/country
or follow-up period and there was no restriction by dose, frequency or
method of drug administration. One author (J. N.) screened the title and
abstract of each reference identified by the search and applied the inclu-
sion criteria. For possibly relevant articles, the full-text article was obtained
and reviewed independently by two out of the three authors (J. N.,
G. O. and S. P. K.). Final inclusion of studies was determined by agreement
of both reviewers and involvement of a third author in case of discrepancy.
After in-depth discussion of the different opinions, the authors agreed
unanimously on the final classification. Only studies published in English
were considered eligible.
Data extraction and quality assessment
Two out of the three authors (J. N., G. O. and S. P. K.) independently
extracted data from included trials. Data extraction was performed
Table 1. Definition of bacteriostatic and bactericidal antibiotics (adapted
from Cohen et al.3)
Bactericidal
aminoglycosides
b-lactams
fluoroquinolones
glycopeptides
lipopeptides
nitroimidazoles and nitrofurans
Bacteriostatic
glycylcyclines
lincosamides
macrolides
oxazolidinones
streptogramins
sulphonamides
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using a standardized data collection form. When missing data were
encountered, the corresponding authors were contacted to retrieve them.
For the assessment of clinical cure, data from ITT populations were
extracted if possible. Some studies did not report the clinical cure rates
of the ITTpopulation or—in case of older studies—did not discern between
different study populations at all. In such a case, results from modified
ITT or PP populations were extracted. In case of the seven studies with
combination therapy, only the microbiologically confirmed cases were
extracted.6 – 12
For mortality analysis, the ITT (‘safety’) population was used through-
out. The primary outcome measures were (i) clinical cure rate as defined
by the investigators in the study and (ii) mortality rate. Data were extracted
as proportions if results were only reported as probability of events or
mortality and if the number of events was not explicitly provided.
Unfortunately, follow-up data and periods of follow-up after end of treat-
ment were heterogeneous.
Subgroup analysis was performed for different diseases and different
classes of antibiotics. Meta-analysis was performed only if at least three
studies included the same disease or antibiotic.
To assess methodological quality and risk of bias, included articles were
examined for (i) randomization process, (ii) blinding, (iii) incomplete out-
come data and (iv) reporting bias/sponsorship as described in the
Cochrane Handbook for Systematic Reviews of Interventions.14
Data synthesis and analysis
Data synthesis was performed using Review Manager (version 5.2, The
Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen,
Denmark). P values ,0.05 were considered statistically significant.
Subgroup analyses for differences between different classes of antibiotics
and differences between different diseases were performed. Because het-
erogeneity was anticipated between studies, a random-effects model was
used for all analyses. Statistical heterogeneity was inspected graphically
(forest plot) and the degree of heterogeneity quantified using the I2 stat-
istic. Publication bias was investigated using a funnel plot in which the
standard error of the effect estimate of each study was plotted against
the estimate. An asymmetric plot suggested possible publication bias.
We used STATA 13 (StataCorp 2013, College Station, TX, USA) for
meta-regression assessing differences between bacteriostatic drug
classes.
Results
Study selection
The literature search yielded 16490 references. After screening
titles and abstracts, 81 articles were selected for full-text screen-
ing (Figure 1). Thirty-three studies met the inclusion criteria
(Table 2). The bacteriostatic agents included tigecycline, linezolid,
macrolides, sulphonamides, tetracyclines and streptogramins.
The bactericidal agents included b-lactam antibiotics, glycopep-
tide antibiotics, fluoroquinolones and aminoglycosides. Diseases
under study included pneumonia (13 studies6,11,15 – 19,21 – 26),
skin and soft tissue infections (8 studies7,8,27 – 32), intra-abdominal
infections (4 studies33 – 36) and others (8 studies10,20,37 – 42). No
trials in neutropenic patients or patients with endocarditis or men-
ingitis met inclusion criteria. All studies except one study on chil-
dren with typhoid included adults only.37
Clinical cure rates
Data from 9597 patients were available for meta-analysis of clin-
ical cure rates. Of these patients, 4717 (49.2%) were treated with
a bacteriostatic agent. Meta-analysis indicated that clinical
cure rates were not different between bactericidal and bacterio-
static drugs [risk ratio (RR), 0.99; 95% CI, 0.97–1.01; P¼0.11;
Figure 2], with an overall heterogeneity of I2¼24%. Analysis of
subgroups was performed on studies using tigecycline, linezolid,
macrolides, b-lactam antibiotics, glycopeptides and fluoroquino-
lones. For the other drug classes, an insufficient number of studies
were found, precluding statistical analysis. Subgroup analyses
revealed that treatment with linezolid appeared to be associated
with better clinical cure rates compared with its bactericidal
comparator (RR, 0.93; 95% CI, 0.87–0.99; P¼0.04; Figure 2). In
meta-regression, combined cure rates of trials using linezolid
were better than those from tigecycline trials (RR, 1.07; 95% CI,
1.02–1.12; P¼0.01). There was no benefit detectable for clinical
cure rates among subgroups of bactericidal antibiotics (Figure 3).
Mortality
The population for the assessment of mortality consisted of
13098 patients in total. There was no significant increase in over-
all mortality in the patient group treated with bacteriostatic anti-
biotics compared with patients treated with bactericidal
antibiotics (RR, 0.91; 95% CI, 0.76 –1.08; P¼0.28; Figure 4).
Heterogeneity was low (I2¼0%). An increased mortality was
found in studies using tigecycline in the bacteriostatic regimen
group (RR, 0.66; 95% CI, 0.46– 0.94; P¼0.02; Figure 4). In
meta-regression, there was a strong trend towards reduced mor-
tality in studies using linezolid compared with tigecycline trials
(RR, 0.64; 95% CI, 0.41–1.00; P¼0.05). There was no mortality
benefit detectable for subgroups of bactericidal antibiotics
(Figure 5).
Relapse
In 12 studies, relapse rates were reported.7,8,17,18,20,34,35,37,39 – 42
Five studies included relapse rates in the clinical cure rate end-
point.17,18,35,39,42 In the remaining seven studies, differences in
relapse rates between bacteriostatic and bactericidal antibiotics
were not significant (RR, 0.76; 95% CI, 0.43–1.35; P¼0.51; data
not shown).
Title and abstract
674 references
Full paper screen
81 references
Excluded
-  Bactericidal antibiotics allowed in
 bacteriostatic group (n = 24)
-  Outpatients included (n = 9)
-  No randomized controlled trial (n = 6)
-  Poor quality of reporting (n = 6)
-  Double publication (n = 3)
Analysed
33 studies
16 490 references
Figure 1. Study selection.
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Table 2. Study characteristics
Author Year Type of study Disease Antibiotics, bactericidal
Antibiotics,
bacteriostatic
Bergallo et al.15 2009 Phase 3, multicentre, double-blind study community-acquired pneumonia levofloxacin tigecycline
Bernard et al.27 1992 prospective, randomized,
multicentre trial
complicated skin and soft tissue
infections
penicillin roxithromycin
Bohte et al.16 1995 open-label, randomized,
multicentre study
community-acquired pneumonia penicillin azithromycin
Breedt et al.28 2005 randomized, double-blind, controlled,
multicentre trial
complicated skin and soft tissue
infections
vancomycin tigecycline
Chen et al.33 2010 Phase 3, multicentre, open-label study complicated intra-abdominal infection imipenem/cilastatin tigecycline
Chuang et al.29 2011 two Phase 3, multicentre, randomized,
double-blind studies
complicated skin and soft tissue
infections
vancomycin/aztreonam tigecycline
Dartois et al.17 2008 randomized, Phase 3, multicentre trial community-acquired pneumonia levofloxacin tigecycline
Ellis-Grosse et al.30 2005 two Phase 3, randomized, double-blind,
multicentre studies
complicated skin and soft tissue
infections
vancomycin/aztreonam tigecycline
Frenck et al.37 2000 randomized, open-label, controlled,
single-centre trial
typhoid fever ceftriaxone azithromycin
Genne et al.18 1997 open-label, prospective, randomized,
single-centre study
community-acquired pneumonia amoxicillin clarithromycin
Itani et al.7 2010 prospective, randomized, open-label,
controlled, multicentre, Phase 4 study
complicated skin and soft tissue
infections
vancomycin linezolid
Jauregui et al.8 2005 randomized, double-blind, controlled,
multicentre, Phase 3 trial
complicated skin and soft tissue
infections
dalbavancin linezolid
Kohno et al.38 2007 randomized, open-label,
comparator-controlled,
multicentre study
nosocomial pneumonia, complicated
skin and soft tissue infections or sepsis
caused by MRSA
vancomycin linezolid
Kuzman et al.19 2005 randomized, open-label,
multicentre study
community-acquired pneumonia cefuroxime azithromycin
Lin et al.10 2008 randomized, double-blind,
comparator-controlled,
multicentre study
pneumonia or complicated skin and soft
tissue infection due to suspected or
known Gram-positive pathogens
vancomycin linezolid
Markowitz et al.39 1992 randomized, double-blind, comparative,
single-centre study
infection with S. aureus vancomycin trimethoprim/
sulfamethoxazole
Mehtar et al.20 1982 open-label, randomized,
single-centre study
severe respiratory tract infections cefuroxime trimethoprim/
sulfamethoxazole
Mwengee et al.40 2006 randomized, controlled, comparative,
open-label trial
plague gentamicin doxycycline
Continued
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Table 2. Continued
Author Year Type of study Disease Antibiotics, bactericidal
Antibiotics,
bacteriostatic
Mokabberi et al.21 2010 prospective, randomized, double-blind,
single-centre trial
community-acquired pneumonia levofloxacin doxycycline
Ode et al.41 1983 open-label, randomized, prospective,
single-centre, Phase 3 trial
acute pyelonephritis ampicillin/mecillinam trimethoprim/
sulfamethoxazole
Oliva et al.34 2005 prospective, randomized, double-blind,
multicentre trial
complicated intra-abdominal infection imipenem tigecycline
Plouffe et al.22 2000 two multicentre, open-label Phase 3
trials, one parallel-group, randomized,
one non-comparative with sequential
inclusion
community-acquired pneumonia cefuroxime azithromycin
Qvist et al.35 2012 randomized, open-label, multicentre,
Phase 3b/4 trial
complicated intra-abdominal infections ceftriaxone/metronidazole tigecycline
Raad et al.42 1999 evaluator-blind, prospective,
randomized, Phase 2, multicentre trial
catheter-related infections vancomycin quinupristin/dalfopristin
Sacchidanand et al.31 2005 Phase 3, randomized, double-blind,
multicentre study
complicated skin and soft tissue
infections
vancomycin/aztreonam tigecycline
San Pedro et al.11 2002 multicentre, randomized, open-label trial pneumonia with Streptococcus
pneumoniae
ceftriaxone/cefpodoxime linezolid
Shanson et al.23 1984 prospective, randomized,
single-centre trial
community-acquired pneumonia ampicillin/flucloxacillin erythromycin
Sterner et al.24 1967 randomized, open-label,
single-centre trial
community-acquired pneumonia cefaloridine erythromycin
Stevens et al.32 2000 randomized, double-blind,
multicentre trial
complicated skin and soft tissue infection oxacillin/dicloxacillin linezolid
Tanaseanu et al.26 2009 prospective, double-blind, non-inferiority,
multicentre, Phase 3 trial
community-acquired pneumonia levofloxacin tigecycline
Tanaseanu et al.25 2008 two Phase 3, multicentre, randomized,
double-blind studies
community-acquired pneumonia levofloxacin tigecycline
Towfigh et al.36 2010 multicentre, open-label, randomized,
Phase 3b/4 study
complicated intra-abdominal infection ceftriaxone/metronidazole tigecycline
Wunderink et al.6 2012 prospective, double-blind, controlled,
multicentre trial
confirmed MRSA pneumonia vancomycin linezolid
System
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Figure 2. RRs for clinical cure rates stratified by use of different bacteriostatic antibiotics. Data markers indicate RRs and error bars indicate 95% CIs.
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Figure 3. RRs for clinical cure rates stratified by use of different bactericidal antibiotics. Data markers indicate RRs and error bars indicate 95% CIs.
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Figure 4. RRs for mortality rates stratified by use of different bacteriostatic antibiotics. Data markers indicate RRs and error bars indicate 95% CIs.
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Figure 5. RRs for mortality rates stratified by use of different bactericidal antibiotics. Data markers indicate RRs and error bars indicate 95% CIs.
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Different diseases
We performed subgroup analyses of the most frequent diseases:
abdominal infections, skin and soft tissue infections and pneumo-
nia. No differences in clinical outcome between diseases could be
found (Figure 6). However, increased mortality was detected in
skin and soft tissue infections treated with bacteriostatic agents
(RR, 0.43; 95% CI, 0.23–0.84; P¼0.01; Figure 7). If studies using
tigecycline were excluded, the difference was no longer significant
(RR, 0.57; 95% CI, 0.26–1.27; P¼0.17), suggesting that this effect
was again due to the increased overall mortality attributed to
tigecycline. Notably, all four studies with abdominal infections
had tigecycline in the bacteriostatic regimen arm without differ-
ence in mortality.
Study quality
The quality of included studies was variable (Figures S2 and S3).
More than half of studies (17/33) were unblinded, resulting in sig-
nificant risk of performance bias. More than 50% of studies were
sponsored by the pharmaceutical company that manufactured
the respective drug and were thus regarded to be at high risk of
reporting bias. Funnel plots did not suggest publication bias
(Figures S4–S7).
Discussion
In our meta-analysis comparing bactericidal with bacteriostatic
antibiotics, no significant differences in clinical cure rates were
found in the diseases under study. Subgroup analysis even sug-
gested that linezolid may have better clinical cure rates if compared
with its bactericidal comparators. This subgroup included severely ill
patients with confirmed MRSA infections, amongst others.6,38
Sufficient antibacterial action of antibiotics in such a patient group
is therefore crucial. As a note of caution, involvement of the sponsor
in the trials using linezolid was substantial and meta-analysis
showed some heterogeneity. Furthermore, vancomycin, which is
difficult to dose appropriately, was the comparator drug in the
majority of studies. Therefore, it is premature to conclude that
linezolid is more efficient than bactericidal antibiotics. However,
our findings suggest that linezolid monotherapy is on par with the
standard bactericidal therapy in this patient group.
Our meta-analysis did not detect differences in overall mortal-
ity between the patient groups. However, there was an increased
mortality associated with the use of tigecycline, an observation in
line with data published recently.43 Meta-regression showed
a trend towards increased mortality of patients treated with tige-
cycline compared with linezolid. The association between
increased mortality and tigecycline was predominantly found
amongst patients with severe skin infections. Remarkably, mortal-
ity was not increased in 931 patients treated with tigecycline for
complicated intra-abdominal infections. An increased mortality in
specific patient populations without differences in clinical cure
rates may have various reasons, such as toxicity of the drug, phar-
macokinetic/pharmacodynamic issues or other reasons.43 Some
authors suggest that the drug may be inadequately dosed,
at least for ventilator-associated pneumonia.44 This may well
explain observed breakthrough bacteraemias as well.45 In
conclusion, increased mortality is probably a specific feature of
tigecycline and not a class effect inherent to all bacteriostatic
drugs. A possible difference from a previously published meta-
analysis on tigecycline is the strict exclusion of concomitant
bactericidal medication.43
It is important to note that the analysis of clinical cure rates and
mortality includes two different populations. Clinical cure rates
included all patients who were followed up adequately; overall
and including all the older studies, they represent a sample that
is closer to PP. The mortality analysis consists of safety data,
resembling to a great extent an ITT population. These two popula-
tions cannot be distinguished by contemporary definitions,
because we included a substantial number of older studies.
Furthermore, it is important to note that the subgroup analyses
are supportive of the main research question, i.e. whether a class
effect between bacteriostatic and bactericidal drugs is detectable.
They should not be regarded as ‘independent’ investigations and
their results should not be overemphasized.
Renowned textbooks suggest that immunocompromised
patients should be treated with bactericidal antibiotics.3,4 Our
analyses include a wide variety of serious bacterial infections,
including respiratory tract infections, complicated abdominal
infections and skin infections. It is widely accepted that a central
pathogenetic feature of most bacterial infections is either local
(e.g. disruption of the membrane integrity, such as injury of the
skin serving for severe skin infection, or obstruction, such as
appendicitis caused by luminal obstruction) or systemic immuno-
suppression (e.g. neutropenia).46 As it is generally assumed that
bacteriostatic antibiotics require a fully functioning immune sys-
tem to kill bacteria, one would expect differences in clinical cure
rates in the patient group receiving bacteriostatic drugs. Our
meta-analysis suggests that this is not the case. Therefore, it
may be hypothesized that either the local immunosuppression
in respiratory tract infections, complicated abdominal infections
and skin infections is not clinically relevant enough to require
the presence of a bactericidal drug or that the biology of bacterial
killing is much more complex than the simplistic concept of bac-
teriostatic versus bactericidal drug activity suggests, even in local
immunosuppression. In any case, our data suggest class indiffer-
ence for infection where the immune system is intact or at least
not impaired in a major way. Based on the data analysed, no con-
clusions regarding severely immunosuppressed patients, such as
patients with neutropenia, can be drawn.
Because of our strict inclusion criteria, we were unable to
include studies assessing neutropenic patients or patients with
endocarditis. These are the ‘classical’ indications for a bactericidal
drug regimen. Only one randomized controlled trial using a bac-
teriostatic drug—linezolid—in patients with neutropenia was
found.47 Unfortunately, a bactericidal add-on medication was
allowed, precluding inclusion in our meta-analysis.47 Thus, the
findings from our work can only be applied to the diseases
under study in our meta-analysis and may not be extended to
endocarditis and neutropenia.
A major theoretical complication of bacteriostatic agents is
relapse of infection after treatment because of the failure to
clear the infection. In the current investigation, there was no
detectable difference in relapse rates between bactericidal and
bacteriostatic antibiotics.
Our study has limitations. To our knowledge, this is the first
study to undertake a meta-analysis on a class effect of drugs.
Therefore, we have no means to measure if the studies included
are heterogeneous enough regarding the three main factors
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(host, pathogen and drug) to conclude that the only difference
between the two patient groups really is the difference between
bacteriostatic and bactericidal antibiotics. There are, however,
sound arguments in favour of such a conclusion. Regarding the
pathogen, we included studies on a wide array of diseases, ran-
ging from Yersinia pestis to methicillin-resistant staphylococci.6,40
Figure 6. RRs for clinical cure rates stratified by different diseases. Data markers indicate RRs and error bars indicate 95% CIs.
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Figure 7. RRs for mortality rates stratified by different diseases. Data markers indicate RRs and error bars indicate 95% CIs.
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Regarding the host, patients with severe local infections such as
severe skin infections or severe abdominal infections were ana-
lysed as well as patients with systemic infections such as salmon-
ellosis or central line-associated infections. Regarding the drugs, a
total of 10 different antibiotic classes were assessed. These differ-
ent drugs may vary significantly in tissue distribution and may
have different effects according to their dosing schedules.
Amongst the bacteriostatic drugs, the newer drugs tigecycline
and linezolid are over-represented. The numbers of patients
included in clinical trials increases over time, probably due to a ris-
ing standard in research practice. This may explain the observed
over-representation of newer bacteriostatic drugs.
The included studies have a significant risk for performance
and publication bias. In general, there may be a publication bias
in favour of bacteriostatic drugs—i.e. linezolid and tigecycline.
However, some studies may have a publication bias in favour of
the bactericidal component as well, as in the case of dalbavancin
compared with linezolid.8
The microbiological definition of bacteriostatic versus bacteri-
cidal suggests a degree of clarity that is not supported by the
evidence. Some drugs labelled as ‘bacteriostatic’ do have ‘bacteri-
cidal’ effects under some in vitro conditions and vice versa.48 For
example, the exchange of culture media—media used for grow-
ing of eukaryotic cells instead of ‘classical’ Mueller –Hinton
broth—may significantly affect drug susceptibility in vitro.49
Thus, it is probably very difficult to predict the action of a given
antibiotic drug in terms of bacteriostatic or bactericidal in an
actual patient with an ongoing bacterial infection. Furthermore,
the action of a given drug may be dependent on the bacterial
load and the interaction with the immune system at the site of
infection. For example, the capacity of neutrophils to phagocytose
bacteria is limited by the sheer quantity of bacteria.50
To our knowledge, this is the first study using clinical data to
investigate the difference between bactericidal and bacteriostatic
antibiotics. Summarized, the data at hand suggest that this clas-
sification is clinically irrelevant if used for abdominal infections,
skin and soft tissue infections and pneumonia. These findings
cannot be applied directly to patients with meningitis, neutro-
penia or endocarditis, because we were unable to include these
types of infection in our meta-analysis.
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